TPST Share Price Performance
US$7.49
-10.58 (-58.55%)
Price US$7.49
Share PriceUS$7.49
TPST Community Narratives
There are no narratives available yet.
Recent TPST News & Updates
No updates
Tempest Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -10.96
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 37.6%
Tempest Therapeutics, Inc. Competitors
About TPST
- Founded
- n/a
- Employees
- 24
- CEO
- WebsiteView website
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading